Arrivo has two clinical-stage pipeline candidates, Forvisirvat (SP-624) for diseases of aging including MASH and RABI-767 for predicted severe acute pancreatitis, each featuring new mechanisms of action, and each targeting the biology of the disease so patients can live longer, healthier lives.